not tagged
Not Tagged
['breast', 'medsir']
phase iii data trial (v. c. tjan-heijnen #esmo22): extension of ai inhibition beyond 5 years of sequential therapy in all postmenopausal women with hr+ breast cancer did not show statistically significant benefit. however, its uses in er+/pr+ pts should be considered. 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM